Ericlam personal page - To The Moon

Ericlam

Ericlam

Eric

739Follow

269Followers

0Topic

0Badge

03-24 06:48

$Vanguard S&P 500 ETF(VOO)$

03-24 06:46

03-23 09:40

03-16

$Dalian Bio-Chem Company Limited(603360)$

03-15

$Sheng Siong(OV8.SI)$

03-14

Colorado changing fireworks tumbler,Tiger cooling fan and Golden brick tissue box is my vote.

03-01

$Taiwan Semiconductor Manufacturing(TSM)$

2025-12-14

$Taiwan Semiconductor Manufacturing(TSM)$

2025-12-14

2025-10-03

Hi My favourite @koolgal

2025-09-19

$BABA-W(09988)$

2025-09-08

$Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276)$

2025-09-05

$FIDUCIAN GROUP LTD(FID.AU)$

2025-08-25

2025-08-20

Great article, would you like to share it?

Xpeng Jumps 5% After Reporting Record Quarterly Revenue, Net Loss Narrows to 5-Year Low

2025-08-20

Great article, would you like to share it?

Financial Report Reveals "Healthy" Signals: Analyzing the Logic Behind JD Health's High-Quality Growth

2025-08-19

$Vanguard S&P 500 ETF(VOO)$

2025-08-14

2025-08-14

2025-08-07

$Vanguard S&P 500 ETF(VOO)$

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3559787818034959","uuid":"3559787818034959","gmtCreate":1596695020477,"gmtModify":1634349872248,"name":"Ericlam","pinyin":"ericlam","introduction":"","introductionEn":"","signature":"Eric","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","hatId":"ca_profile_frame_DWr5S1","hatName":"","vip":1,"status":2,"fanSize":269,"headSize":739,"tweetSize":1023,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-4","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Tiger Star","description":"Join the tiger community for 2000 days","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.01.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.24","exceedPercentage":"80.00%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.30","exceedPercentage":"60.57%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-4","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Tiger Star","description":"Join the tiger community for 2000 days","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.01.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":35,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":545976004883376,"gmtCreate":1774306093525,"gmtModify":1774306097077,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/VOO\">$Vanguard S&amp;P 500 ETF(VOO)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/VOO\">$Vanguard S&amp;P 500 ETF(VOO)$&nbsp;</a>&nbsp;","text":"$Vanguard S&P 500 ETF(VOO)$","images":[{"img":"https://community-static.tradeup.com/news/7f778e8a097920fc5447532bba4bfcbc","width":"924","height":"1536"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/545976004883376","isVote":1,"tweetType":1,"viewCount":34,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":545976147727728,"gmtCreate":1774306004763,"gmtModify":1774306008502,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/QLYS\">$Qualys(QLYS)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/QLYS\">$Qualys(QLYS)$</a>&nbsp;","text":"$Qualys(QLYS)$","images":[{"img":"https://community-static.tradeup.com/news/ad455aaad36d4579753d78b2a02eddac","width":"924","height":"1536"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/545976147727728","isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":545664841553688,"gmtCreate":1774230024778,"gmtModify":1774230028257,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/QLYS\">$Qualys(QLYS)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/QLYS\">$Qualys(QLYS)$</a>&nbsp;","text":"$Qualys(QLYS)$","images":[{"img":"https://community-static.tradeup.com/news/406c708e3430521725ec2a81c335eb13","width":"924","height":"1536"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/545664841553688","isVote":1,"tweetType":1,"viewCount":10,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":543092213580808,"gmtCreate":1773618801739,"gmtModify":1773618805405,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/603360\">$Dalian Bio-Chem Company Limited(603360)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/603360\">$Dalian Bio-Chem Company Limited(603360)$</a>&nbsp;","text":"$Dalian Bio-Chem Company Limited(603360)$","images":[{"img":"https://community-static.tradeup.com/news/75c8846e77a9cc40e55f3c599a671512","width":"924","height":"1536"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/543092213580808","isVote":1,"tweetType":1,"viewCount":62,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":542756544225936,"gmtCreate":1773536717880,"gmtModify":1773536721618,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/OV8.SI\">$Sheng Siong(OV8.SI)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/OV8.SI\">$Sheng Siong(OV8.SI)$&nbsp;</a>&nbsp;","text":"$Sheng Siong(OV8.SI)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/542756544225936","isVote":1,"tweetType":1,"viewCount":258,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":542382101480408,"gmtCreate":1773445433070,"gmtModify":1773445437387,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"htmlText":"Colorado changing fireworks tumbler,Tiger cooling fan and Golden brick tissue box is my vote.","listText":"Colorado changing fireworks tumbler,Tiger cooling fan and Golden brick tissue box is my vote.","text":"Colorado changing fireworks tumbler,Tiger cooling fan and Golden brick tissue box is my vote.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/542382101480408","isVote":1,"tweetType":1,"viewCount":237,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":537814455231200,"gmtCreate":1772324034013,"gmtModify":1772324037614,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/TSM\">$Taiwan Semiconductor Manufacturing(TSM)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/TSM\">$Taiwan Semiconductor Manufacturing(TSM)$&nbsp;</a>&nbsp;","text":"$Taiwan Semiconductor Manufacturing(TSM)$","images":[{"img":"https://community-static.tradeup.com/news/1ad05175ae79b8038d6daa2a6caff357","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/537814455231200","isVote":1,"tweetType":1,"viewCount":162,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":510604230484112,"gmtCreate":1765672845715,"gmtModify":1765672849214,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/TSM\">$Taiwan Semiconductor Manufacturing(TSM)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/TSM\">$Taiwan Semiconductor Manufacturing(TSM)$&nbsp;</a>&nbsp;","text":"$Taiwan Semiconductor Manufacturing(TSM)$","images":[{"img":"https://community-static.tradeup.com/news/a383aa1ce4f76905a83038a9103152bc","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/510604230484112","isVote":1,"tweetType":1,"viewCount":1407,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":510574240498296,"gmtCreate":1765665613696,"gmtModify":1765665617428,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/QLYS\">$Qualys(QLYS)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/QLYS\">$Qualys(QLYS)$</a>&nbsp;","text":"$Qualys(QLYS)$","images":[{"img":"https://community-static.tradeup.com/news/a05d5ff76d8818f25326c816c20ac48f","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/510574240498296","isVote":1,"tweetType":1,"viewCount":1293,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":485087308755792,"gmtCreate":1759459855439,"gmtModify":1759461504605,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"htmlText":"Hi My favourite <a href=\"https://ttm.financial/U/3559581955535845\"> @koolgal </a>","listText":"Hi My favourite <a href=\"https://ttm.financial/U/3559581955535845\"> @koolgal </a>","text":"Hi My favourite @koolgal","images":[{"img":"https://community-static.tradeup.com/news/720e2d95a75429d8e9ab6b284a97e717"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/485087308755792","isVote":1,"tweetType":1,"viewCount":1146,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":480111153767136,"gmtCreate":1758238798216,"gmtModify":1758238801822,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/09988\">$BABA-W(09988)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/09988\">$BABA-W(09988)$&nbsp;</a>&nbsp;","text":"$BABA-W(09988)$","images":[{"img":"https://community-static.tradeup.com/news/51e331263837b3741fd7e02c5bad443f","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/480111153767136","isVote":1,"tweetType":1,"viewCount":1796,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":476208223433544,"gmtCreate":1757289096158,"gmtModify":1757296499895,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/600276\">$Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/600276\">$Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276)$</a>&nbsp;","text":"$Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276)$","images":[{"img":"https://community-static.tradeup.com/news/0ad5f6a1cee5b95385d092aae759fdee","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/476208223433544","isVote":1,"tweetType":1,"viewCount":1822,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":475131775918840,"gmtCreate":1757022475995,"gmtModify":1757022638041,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/FID.AU\">$FIDUCIAN GROUP LTD(FID.AU)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/FID.AU\">$FIDUCIAN GROUP LTD(FID.AU)$</a>&nbsp;","text":"$FIDUCIAN GROUP LTD(FID.AU)$","images":[{"img":"https://community-static.tradeup.com/news/248e45a8621df1c4a88657891638a9e6","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/475131775918840","isVote":1,"tweetType":1,"viewCount":1602,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":471234502746464,"gmtCreate":1756084841629,"gmtModify":1756084844798,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/00867\">$CMS(00867)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/00867\">$CMS(00867)$</a>&nbsp;","text":"$CMS(00867)$","images":[{"img":"https://community-static.tradeup.com/news/44c5ad08ffdae6eda34c96f9aa6e8de0","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/471234502746464","isVote":1,"tweetType":1,"viewCount":2041,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":469452052877360,"gmtCreate":1755650397737,"gmtModify":1755650400212,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/469452052877360","repostId":"2560161971","repostType":4,"repost":{"id":"2560161971","kind":"live","pubTimestamp":1755614108,"share":"https://ttm.financial/m/news/2560161971?lang=en_US&edition=fundamental","pubTime":"2025-08-19 22:35","market":"us","language":"en","title":"Xpeng Jumps 5% After Reporting Record Quarterly Revenue, Net Loss Narrows to 5-Year Low","url":"https://stock-news.laohu8.com/highlight/detail?id=2560161971","media":"CnEVPost","summary":"Xpeng reported record quarterly revenue and further reduced its net loss to a five-year low, driven ","content":"<div>\n<p>Xpeng reported record quarterly revenue and further reduced its net loss to a five-year low, driven by strong growth in vehicle deliveries.XPeng’s U.S.-listed shares jumped 5% while its rival NIO ...</p>\n\n<a href=\"https://cnevpost.com/2025/08/19/xpeng-q2-2025-earnings/\">Source Link</a>\n\n</div>\n","source":"cnevpost_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xpeng Jumps 5% After Reporting Record Quarterly Revenue, Net Loss Narrows to 5-Year Low</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXpeng Jumps 5% After Reporting Record Quarterly Revenue, Net Loss Narrows to 5-Year Low\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-19 22:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://cnevpost.com/2025/08/19/xpeng-q2-2025-earnings/><strong>CnEVPost</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Xpeng reported record quarterly revenue and further reduced its net loss to a five-year low, driven by strong growth in vehicle deliveries.XPeng’s U.S.-listed shares jumped 5% while its rival NIO ...</p>\n\n<a href=\"https://cnevpost.com/2025/08/19/xpeng-q2-2025-earnings/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1119":"汽车制造商","BK1588":"回港中概股","BK1610":"ETF&股票定投概念","09868":"小鹏汽车-W","BK1587":"次新股","BK1575":"同股不同权","XPEV":"小鹏汽车","BK1539":"汽车股","LU0593848301.USD":"未来资产亚洲卓越消费股票基金A"},"source_url":"https://cnevpost.com/2025/08/19/xpeng-q2-2025-earnings/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2560161971","content_text":"Xpeng reported record quarterly revenue and further reduced its net loss to a five-year low, driven by strong growth in vehicle deliveries.XPeng’s U.S.-listed shares jumped 5% while its rival NIO gained over 6%The company reported revenue of RMB 18.27 billion ($2.55 billion) for the second quarter, up 125.3 percent year-on-year and up 15.6 percent quarter-on-quarter, according to its unaudited financial results released today.Notably, this marks Xpeng's highest quarterly revenue on record, though it still fell slightly short of Wall Street analysts' expectations of RMB 18.38 billion.In the second quarter, Xpeng delivered a record 103,181 vehicles, within the guidance range of 102,000 to 108,000 vehicles, slightly below analysts' expectations of 105,000 vehicles.Deliveries for the quarter increased by 241.58 percent year-on-year and up 9.76 percent quarter-on-quarter.Xpeng's net loss for the second quarter was RMB 480 million, a new low since the third quarter of 2020, representing a year-on-year decrease of 62.81 percent and a quarter-on-quarter decrease of 28.05 percent.Under non-GAAP, adjusted net loss for the second quarter was RMB 390 million, compared to RMB 1.22 billion in the same period of 2024 and RMB 430 million in the first quarter of 2025.Xpeng's second-quarter revenues from vehicle sales was RMB 16.88 billion, up 147.6 percent year-on-year and up 17.5 percent quarter-on-quarter, primarily driven by increased vehicle deliveries.Its second-quarter service and other revenue was RMB 1.39 billion, up 7.6 percent year-on-year but down 3.5 percent quarter-on-quarter.The year-on-year increase was primarily attributable to growth in revenue from parts and accessories sales as cumulative vehicle sales increased. The quarter-on-quarter decrease was primarily attributable to fluctuations in revenue from technology R&D services, Xpeng said.The company's gross margin for the second quarter was a record 17.3 percent, compared to 14.0 percent in the same period of 2024 and 15.6 percent in the first quarter.Xpeng reports record quarterly revenue, net loss narrows to 5-year lowThe second-quarter vehicle margin reached a record 14.3 percent, compared to 6.4 percent in the same period of 2024 and 10.5 percent in the first quarter of 2025. These increases were primarily attributed to ongoing cost reductions and optimization of the vehicle model product mix, according to Xpeng.Xpeng reports record quarterly revenue, net loss narrows to 5-year lowThe company's service and others margin for the second quarter was 53.6 percent, compared to 54.3 percent in the same period of 2024 and 66.4 percent in the first quarter. The sequential decline was primarily due to fluctuations related to technology R&D services.The company's R&D expenses for the second quarter were RMB 2.21 billion, up 50.4 percent year-on-year and up 11.4 percent quarter-on-quarter, mainly due to increased expenses related to new vehicle models and technology development.Sales, general and administrative expenses for the second quarter were RMB 2.17 billion, up 37.7 percent year-on-year and up 11.4 percent quarter-on-quarter. This was mainly due to increased franchisee commissions, marketing and advertising expenses.As of June 30, 2025, the company held cash and cash equivalents, restricted cash, short-term investments, and time deposits totaling RMB 47.57 billion, compared to RMB 41.96 billion as of December 31, 2025.Xpeng guided third-quarter vehicle deliveries to be between 113,000 and 118,000 units, representing a year-on-year increase of about 142.8 percent to 153.6 percent.This guidance implies that Xpeng expects to deliver a cumulative total of 76,283 to 81,283 vehicles in August and September, considering the 36,717 vehicles delivered in July.The company guided third-quarter revenue to be between RMB 19.6 billion and RMB 21.0 billion, representing a year-on-year increase of about 94.0 percent to 107.9 percent.","news_type":1,"symbols_score_info":{"XPEV":1.1,"09868":0.9}},"isVote":1,"tweetType":1,"viewCount":1974,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":469405530288168,"gmtCreate":1755650306356,"gmtModify":1755650308601,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/469405530288168","repostId":"1116300138","repostType":2,"repost":{"id":"1116300138","kind":"news","weMediaInfo":{"introduction":"Global Stock Market Deep Analysis","home_visible":1,"media_name":"Deep News","id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"pubTimestamp":1755612253,"share":"https://ttm.financial/m/news/1116300138?lang=en_US&edition=fundamental","pubTime":"2025-08-19 22:04","market":"fut","language":"en","title":"Financial Report Reveals \"Healthy\" Signals: Analyzing the Logic Behind JD Health's High-Quality Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1116300138","media":"Deep News","summary":"As a leading player in China's digital health market, JD Health has maintained clear development priorities in recent years: continuously strengthening supply chain capabilities as the foundation of...","content":"<p>As a leading player in China's digital health market, JD Health has maintained clear development priorities in recent years: continuously strengthening supply chain capabilities as the foundation of business operations, while focusing on enhancing medical service capabilities, particularly building integrated online and offline service systems and complete service loops.</p>\n<p>In JD Health's underlying business logic, empowering partners represents a crucial component, making collaborative growth with partners one of JD Health's long-term strategies. Business-related dynamic events serve as important windows for investors to observe how JD Health advances its long-term strategy.</p>\n<p>On August 15, the day after announcing its interim results, JD Health reached a strategic cooperation agreement with Eisai China. Through this partnership, Lemborexant (brand name: Dayvigo), an insomnia treatment drug developed by Eisai China, will launch exclusively online through JD Health following regulatory approval. Lemborexant represents China's first non-sedating anti-insomnia new drug, potentially reshaping the anti-insomnia pharmaceutical market.</p>\n<p>This development aligns with strengthening supply chain advantages and corresponds to JD Health's core long-term development direction. The interim financial report released on August 14 showed that over 30 innovative drugs launched online through JD Health in the first half of this year, alongside collaborations with multiple medical device and nutritional health brands, achieving online debuts for numerous products across the entire network.</p>\n<p>These developments confirm JD Health's efforts to further consolidate its core competitive advantages: supply chain capabilities and brand empowerment value. The synergy between these elements has facilitated extensive collaborations, creating advantages in debut product quantities beyond the existing advantages in pharmaceutical and health product category numbers.</p>\n<p>**Service Model Innovation Becomes Second Growth Curve**</p>\n<p>In recent years, a core trend in the digital medical industry has been online-offline integration. Major players are refining traditional online channel capabilities while prioritizing the fusion of online and offline services and complete connectivity across the entire chain.</p>\n<p>For internet medical companies like JD Health, the main business includes pharmaceutical retail and medical services. The business core integrates these two major segments, creating a complete \"medical testing, diagnosis, and medication\" service loop. Internet hospitals serve as key components in this service loop, with their service capabilities in various disease specialties directly determining service depth and breadth.</p>\n<p>Through long-term development, JD Health has effectively explored internet medical specialty service models in five major areas: dermatology, mental health, traditional Chinese medicine, oncology, and men's health.</p>\n<p>As a new-type medical health service enterprise, JD Health focuses on deepening and specializing online services while emphasizing \"home delivery\" capabilities for offline services. Examples include nurse home visits and home rapid testing services, with service levels primarily reflected in \"breadth\" and \"speed.\"</p>\n<p>\"Breadth\" refers to nurse home visit services expanding to 7 categories and 64 items, while home rapid testing currently provides over 160 rapid testing services. \"Speed\" means nurse home visits can achieve order acceptance in as fast as 3 minutes and door-to-door service within 1 hour.</p>\n<p>These service capabilities demonstrate their value in specific demand scenarios. Taking flu as an example, during flu season, users can quickly determine flu types through JD Health's home rapid testing service, with subsequent consultations, medication purchases, and follow-ups completed online, typically finishing the entire process within one day.</p>\n<p>**Weight Management Business Layout Demonstrates Strategic Extension**</p>\n<p>JD Health's weight management business layout represents both an extension of existing business strategy and a typical case of multi-win outcomes. This year, weight management has become a nationally discussed topic, driven by continuously growing obesity populations and sustained strong demand, alongside GLP-1 drugs like semaglutide expanding into weight loss indications, reshaping the weight loss drug market and accelerating market growth.</p>\n<p>Based on current market expectations, GLP-1 drugs with weight loss indications could reach trillion-scale market potential. JD Health's related business layout includes strategic cooperation with Novo Nordisk, the original developer of semaglutide. Mazdutide (brand name: Xinermei) from Innovent Biologics launched exclusively on JD Health immediately after approval, with search volume for \"Xinermei\" exceeding one million on the JD platform between July 4 and August 4, serving over 30,000 users.</p>\n<p>**User Growth and Stickiness Drive Performance Improvement**</p>\n<p>JD Health's 2025 interim financial report shows revenue of 35.3 billion yuan in the first half of 2025, representing 24.5% year-over-year growth, not only exceeding market expectations but achieving the strongest half-year growth rate since the end of the pandemic in 2023. Operationally, active users exceeded 200 million by the first half of 2025, achieving a milestone breakthrough.</p>\n<p>The core highlights of JD Health's financial report are revenue growth and attribution for pharmaceutical e-commerce and medical services, the two main businesses. Pharmaceutical e-commerce has maintained revenue proportions above 83% in recent years, serving as the company's performance foundation, achieving 29.3 billion yuan revenue in the first half of 2025, up 23% year-over-year.</p>\n<p>Medical services have shown stronger growth momentum than pharmaceutical e-commerce in recent years, serving as an important marginal force driving company performance growth, with first-half revenue of 6 billion yuan, up 34% year-over-year.</p>\n<p>Pharmaceutical e-commerce revenue growth primarily benefits from active user growth and increased per-user purchase amounts, essentially reflecting how supply chain and service capabilities support continuous product category enrichment and complete service loop experience optimization, creating positive resonance with JD Health's brand value and improving user mindshare and online sales penetration during the reporting period.</p>\n<p>**AI Upgrade Provides Important Valuation Support**</p>\n<p>Following the financial report release, investors responded positively to JD Health's performance, with the company's stock price surging 21% cumulatively over two trading days on August 15 and 18. Particularly on August 15, the day after the financial report release, intraday gains exceeded 16% at their peak, ultimately closing up 12%.</p>\n<p>JD Health's post-earnings stock surge stems partly from market recognition of its performance and underlying business model. Leveraging supply chain advantages, JD Health has built an integrated \"supply chain + service + technology\" ecosystem and complete \"medical testing, diagnosis, and medication\" service loop, creating significant differentiation from peers and demonstrating considerable scarcity value in capital markets due to its difficult-to-replicate characteristics.</p>\n<p>Another factor is investor response to JD Health's strong AI concept attributes. According to this quarter's financial report, JD Health launched the \"AI Jingyi\" product series in the first half of this year, covering multi-role professional service intelligent agents for users, including AI doctors, AI pharmacists, and AI psychological counselors, along with digital avatars and AI assistants for doctors. During the reporting period, \"AI Jingyi\" served over 50 million users cumulatively.</p>\n<p>For hospital AI upgrades, JD Health introduced its first hospital full-scenario product \"JD Zhuoyi,\" primarily providing AI upgrades for three main \"entities\": individual users, doctors, and hospital operations management. This has been implemented in multiple medical institutions, such as the AI-driven outpatient patient service process loop created through JD Health's collaboration with the First Affiliated Hospital of Wenzhou Medical University, which has served over 2.2 million patient visits.</p>\n<p>Currently, AI field attention has shifted toward applications, and JD Health, as an important industry participant, has continuously focused on application-level development in AI upgrades in recent years, aligning with industry trends while achieving significant results.</p>\n<p>Long-term, JD Health's continued investment and innovation in AI may break through traditional internet medical enterprise growth bottlenecks, with AI's role as a third growth curve becoming increasingly prominent, helping the company improve valuation levels in capital markets.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Financial Report Reveals \"Healthy\" Signals: Analyzing the Logic Behind JD Health's High-Quality Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFinancial Report Reveals \"Healthy\" Signals: Analyzing the Logic Behind JD Health's High-Quality Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-08-19 22:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>As a leading player in China's digital health market, JD Health has maintained clear development priorities in recent years: continuously strengthening supply chain capabilities as the foundation of business operations, while focusing on enhancing medical service capabilities, particularly building integrated online and offline service systems and complete service loops.</p>\n<p>In JD Health's underlying business logic, empowering partners represents a crucial component, making collaborative growth with partners one of JD Health's long-term strategies. Business-related dynamic events serve as important windows for investors to observe how JD Health advances its long-term strategy.</p>\n<p>On August 15, the day after announcing its interim results, JD Health reached a strategic cooperation agreement with Eisai China. Through this partnership, Lemborexant (brand name: Dayvigo), an insomnia treatment drug developed by Eisai China, will launch exclusively online through JD Health following regulatory approval. Lemborexant represents China's first non-sedating anti-insomnia new drug, potentially reshaping the anti-insomnia pharmaceutical market.</p>\n<p>This development aligns with strengthening supply chain advantages and corresponds to JD Health's core long-term development direction. The interim financial report released on August 14 showed that over 30 innovative drugs launched online through JD Health in the first half of this year, alongside collaborations with multiple medical device and nutritional health brands, achieving online debuts for numerous products across the entire network.</p>\n<p>These developments confirm JD Health's efforts to further consolidate its core competitive advantages: supply chain capabilities and brand empowerment value. The synergy between these elements has facilitated extensive collaborations, creating advantages in debut product quantities beyond the existing advantages in pharmaceutical and health product category numbers.</p>\n<p>**Service Model Innovation Becomes Second Growth Curve**</p>\n<p>In recent years, a core trend in the digital medical industry has been online-offline integration. Major players are refining traditional online channel capabilities while prioritizing the fusion of online and offline services and complete connectivity across the entire chain.</p>\n<p>For internet medical companies like JD Health, the main business includes pharmaceutical retail and medical services. The business core integrates these two major segments, creating a complete \"medical testing, diagnosis, and medication\" service loop. Internet hospitals serve as key components in this service loop, with their service capabilities in various disease specialties directly determining service depth and breadth.</p>\n<p>Through long-term development, JD Health has effectively explored internet medical specialty service models in five major areas: dermatology, mental health, traditional Chinese medicine, oncology, and men's health.</p>\n<p>As a new-type medical health service enterprise, JD Health focuses on deepening and specializing online services while emphasizing \"home delivery\" capabilities for offline services. Examples include nurse home visits and home rapid testing services, with service levels primarily reflected in \"breadth\" and \"speed.\"</p>\n<p>\"Breadth\" refers to nurse home visit services expanding to 7 categories and 64 items, while home rapid testing currently provides over 160 rapid testing services. \"Speed\" means nurse home visits can achieve order acceptance in as fast as 3 minutes and door-to-door service within 1 hour.</p>\n<p>These service capabilities demonstrate their value in specific demand scenarios. Taking flu as an example, during flu season, users can quickly determine flu types through JD Health's home rapid testing service, with subsequent consultations, medication purchases, and follow-ups completed online, typically finishing the entire process within one day.</p>\n<p>**Weight Management Business Layout Demonstrates Strategic Extension**</p>\n<p>JD Health's weight management business layout represents both an extension of existing business strategy and a typical case of multi-win outcomes. This year, weight management has become a nationally discussed topic, driven by continuously growing obesity populations and sustained strong demand, alongside GLP-1 drugs like semaglutide expanding into weight loss indications, reshaping the weight loss drug market and accelerating market growth.</p>\n<p>Based on current market expectations, GLP-1 drugs with weight loss indications could reach trillion-scale market potential. JD Health's related business layout includes strategic cooperation with Novo Nordisk, the original developer of semaglutide. Mazdutide (brand name: Xinermei) from Innovent Biologics launched exclusively on JD Health immediately after approval, with search volume for \"Xinermei\" exceeding one million on the JD platform between July 4 and August 4, serving over 30,000 users.</p>\n<p>**User Growth and Stickiness Drive Performance Improvement**</p>\n<p>JD Health's 2025 interim financial report shows revenue of 35.3 billion yuan in the first half of 2025, representing 24.5% year-over-year growth, not only exceeding market expectations but achieving the strongest half-year growth rate since the end of the pandemic in 2023. Operationally, active users exceeded 200 million by the first half of 2025, achieving a milestone breakthrough.</p>\n<p>The core highlights of JD Health's financial report are revenue growth and attribution for pharmaceutical e-commerce and medical services, the two main businesses. Pharmaceutical e-commerce has maintained revenue proportions above 83% in recent years, serving as the company's performance foundation, achieving 29.3 billion yuan revenue in the first half of 2025, up 23% year-over-year.</p>\n<p>Medical services have shown stronger growth momentum than pharmaceutical e-commerce in recent years, serving as an important marginal force driving company performance growth, with first-half revenue of 6 billion yuan, up 34% year-over-year.</p>\n<p>Pharmaceutical e-commerce revenue growth primarily benefits from active user growth and increased per-user purchase amounts, essentially reflecting how supply chain and service capabilities support continuous product category enrichment and complete service loop experience optimization, creating positive resonance with JD Health's brand value and improving user mindshare and online sales penetration during the reporting period.</p>\n<p>**AI Upgrade Provides Important Valuation Support**</p>\n<p>Following the financial report release, investors responded positively to JD Health's performance, with the company's stock price surging 21% cumulatively over two trading days on August 15 and 18. Particularly on August 15, the day after the financial report release, intraday gains exceeded 16% at their peak, ultimately closing up 12%.</p>\n<p>JD Health's post-earnings stock surge stems partly from market recognition of its performance and underlying business model. Leveraging supply chain advantages, JD Health has built an integrated \"supply chain + service + technology\" ecosystem and complete \"medical testing, diagnosis, and medication\" service loop, creating significant differentiation from peers and demonstrating considerable scarcity value in capital markets due to its difficult-to-replicate characteristics.</p>\n<p>Another factor is investor response to JD Health's strong AI concept attributes. According to this quarter's financial report, JD Health launched the \"AI Jingyi\" product series in the first half of this year, covering multi-role professional service intelligent agents for users, including AI doctors, AI pharmacists, and AI psychological counselors, along with digital avatars and AI assistants for doctors. During the reporting period, \"AI Jingyi\" served over 50 million users cumulatively.</p>\n<p>For hospital AI upgrades, JD Health introduced its first hospital full-scenario product \"JD Zhuoyi,\" primarily providing AI upgrades for three main \"entities\": individual users, doctors, and hospital operations management. This has been implemented in multiple medical institutions, such as the AI-driven outpatient patient service process loop created through JD Health's collaboration with the First Affiliated Hospital of Wenzhou Medical University, which has served over 2.2 million patient visits.</p>\n<p>Currently, AI field attention has shifted toward applications, and JD Health, as an important industry participant, has continuously focused on application-level development in AI upgrades in recent years, aligning with industry trends while achieving significant results.</p>\n<p>Long-term, JD Health's continued investment and innovation in AI may break through traditional internet medical enterprise growth bottlenecks, with AI's role as a third growth curve becoming increasingly prominent, helping the company improve valuation levels in capital markets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"86618":"京东健康-R","BK1142":"互联网与直销零售","BK1591":"就地过年概念","BK1615":"港股-互联网","LU0051755006.USD":"摩根大通中国A (dist)","BK1515":"抗疫概念","BK1247":"药品零售","BK1583":"高瓴概念","BK1571":"互联网医疗","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","BK1589":"北水核心资产","06618":"京东健康"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116300138","content_text":"As a leading player in China's digital health market, JD Health has maintained clear development priorities in recent years: continuously strengthening supply chain capabilities as the foundation of business operations, while focusing on enhancing medical service capabilities, particularly building integrated online and offline service systems and complete service loops.\nIn JD Health's underlying business logic, empowering partners represents a crucial component, making collaborative growth with partners one of JD Health's long-term strategies. Business-related dynamic events serve as important windows for investors to observe how JD Health advances its long-term strategy.\nOn August 15, the day after announcing its interim results, JD Health reached a strategic cooperation agreement with Eisai China. Through this partnership, Lemborexant (brand name: Dayvigo), an insomnia treatment drug developed by Eisai China, will launch exclusively online through JD Health following regulatory approval. Lemborexant represents China's first non-sedating anti-insomnia new drug, potentially reshaping the anti-insomnia pharmaceutical market.\nThis development aligns with strengthening supply chain advantages and corresponds to JD Health's core long-term development direction. The interim financial report released on August 14 showed that over 30 innovative drugs launched online through JD Health in the first half of this year, alongside collaborations with multiple medical device and nutritional health brands, achieving online debuts for numerous products across the entire network.\nThese developments confirm JD Health's efforts to further consolidate its core competitive advantages: supply chain capabilities and brand empowerment value. The synergy between these elements has facilitated extensive collaborations, creating advantages in debut product quantities beyond the existing advantages in pharmaceutical and health product category numbers.\n**Service Model Innovation Becomes Second Growth Curve**\nIn recent years, a core trend in the digital medical industry has been online-offline integration. Major players are refining traditional online channel capabilities while prioritizing the fusion of online and offline services and complete connectivity across the entire chain.\nFor internet medical companies like JD Health, the main business includes pharmaceutical retail and medical services. The business core integrates these two major segments, creating a complete \"medical testing, diagnosis, and medication\" service loop. Internet hospitals serve as key components in this service loop, with their service capabilities in various disease specialties directly determining service depth and breadth.\nThrough long-term development, JD Health has effectively explored internet medical specialty service models in five major areas: dermatology, mental health, traditional Chinese medicine, oncology, and men's health.\nAs a new-type medical health service enterprise, JD Health focuses on deepening and specializing online services while emphasizing \"home delivery\" capabilities for offline services. Examples include nurse home visits and home rapid testing services, with service levels primarily reflected in \"breadth\" and \"speed.\"\n\"Breadth\" refers to nurse home visit services expanding to 7 categories and 64 items, while home rapid testing currently provides over 160 rapid testing services. \"Speed\" means nurse home visits can achieve order acceptance in as fast as 3 minutes and door-to-door service within 1 hour.\nThese service capabilities demonstrate their value in specific demand scenarios. Taking flu as an example, during flu season, users can quickly determine flu types through JD Health's home rapid testing service, with subsequent consultations, medication purchases, and follow-ups completed online, typically finishing the entire process within one day.\n**Weight Management Business Layout Demonstrates Strategic Extension**\nJD Health's weight management business layout represents both an extension of existing business strategy and a typical case of multi-win outcomes. This year, weight management has become a nationally discussed topic, driven by continuously growing obesity populations and sustained strong demand, alongside GLP-1 drugs like semaglutide expanding into weight loss indications, reshaping the weight loss drug market and accelerating market growth.\nBased on current market expectations, GLP-1 drugs with weight loss indications could reach trillion-scale market potential. JD Health's related business layout includes strategic cooperation with Novo Nordisk, the original developer of semaglutide. Mazdutide (brand name: Xinermei) from Innovent Biologics launched exclusively on JD Health immediately after approval, with search volume for \"Xinermei\" exceeding one million on the JD platform between July 4 and August 4, serving over 30,000 users.\n**User Growth and Stickiness Drive Performance Improvement**\nJD Health's 2025 interim financial report shows revenue of 35.3 billion yuan in the first half of 2025, representing 24.5% year-over-year growth, not only exceeding market expectations but achieving the strongest half-year growth rate since the end of the pandemic in 2023. Operationally, active users exceeded 200 million by the first half of 2025, achieving a milestone breakthrough.\nThe core highlights of JD Health's financial report are revenue growth and attribution for pharmaceutical e-commerce and medical services, the two main businesses. Pharmaceutical e-commerce has maintained revenue proportions above 83% in recent years, serving as the company's performance foundation, achieving 29.3 billion yuan revenue in the first half of 2025, up 23% year-over-year.\nMedical services have shown stronger growth momentum than pharmaceutical e-commerce in recent years, serving as an important marginal force driving company performance growth, with first-half revenue of 6 billion yuan, up 34% year-over-year.\nPharmaceutical e-commerce revenue growth primarily benefits from active user growth and increased per-user purchase amounts, essentially reflecting how supply chain and service capabilities support continuous product category enrichment and complete service loop experience optimization, creating positive resonance with JD Health's brand value and improving user mindshare and online sales penetration during the reporting period.\n**AI Upgrade Provides Important Valuation Support**\nFollowing the financial report release, investors responded positively to JD Health's performance, with the company's stock price surging 21% cumulatively over two trading days on August 15 and 18. Particularly on August 15, the day after the financial report release, intraday gains exceeded 16% at their peak, ultimately closing up 12%.\nJD Health's post-earnings stock surge stems partly from market recognition of its performance and underlying business model. Leveraging supply chain advantages, JD Health has built an integrated \"supply chain + service + technology\" ecosystem and complete \"medical testing, diagnosis, and medication\" service loop, creating significant differentiation from peers and demonstrating considerable scarcity value in capital markets due to its difficult-to-replicate characteristics.\nAnother factor is investor response to JD Health's strong AI concept attributes. According to this quarter's financial report, JD Health launched the \"AI Jingyi\" product series in the first half of this year, covering multi-role professional service intelligent agents for users, including AI doctors, AI pharmacists, and AI psychological counselors, along with digital avatars and AI assistants for doctors. During the reporting period, \"AI Jingyi\" served over 50 million users cumulatively.\nFor hospital AI upgrades, JD Health introduced its first hospital full-scenario product \"JD Zhuoyi,\" primarily providing AI upgrades for three main \"entities\": individual users, doctors, and hospital operations management. This has been implemented in multiple medical institutions, such as the AI-driven outpatient patient service process loop created through JD Health's collaboration with the First Affiliated Hospital of Wenzhou Medical University, which has served over 2.2 million patient visits.\nCurrently, AI field attention has shifted toward applications, and JD Health, as an important industry participant, has continuously focused on application-level development in AI upgrades in recent years, aligning with industry trends while achieving significant results.\nLong-term, JD Health's continued investment and innovation in AI may break through traditional internet medical enterprise growth bottlenecks, with AI's role as a third growth curve becoming increasingly prominent, helping the company improve valuation levels in capital markets.","news_type":1,"symbols_score_info":{"86618":1,"06618":1}},"isVote":1,"tweetType":1,"viewCount":2056,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":469094972682488,"gmtCreate":1755563222160,"gmtModify":1755563225370,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/VOO\">$Vanguard S&amp;P 500 ETF(VOO)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/VOO\">$Vanguard S&amp;P 500 ETF(VOO)$&nbsp;</a>&nbsp;","text":"$Vanguard S&P 500 ETF(VOO)$","images":[{"img":"https://community-static.tradeup.com/news/dfc55a21543d084bf21a1eba482048ce","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/469094972682488","isVote":1,"tweetType":1,"viewCount":2079,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":467325755576760,"gmtCreate":1755130860018,"gmtModify":1755130862916,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$&nbsp;</a>&nbsp;","text":"$Apple(AAPL)$","images":[{"img":"https://community-static.tradeup.com/news/dae3476fea5fc10b72d58b8b033966d7","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/467325755576760","isVote":1,"tweetType":1,"viewCount":1206,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":467325531677376,"gmtCreate":1755130806244,"gmtModify":1755130810649,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$&nbsp;</a>&nbsp;","text":"$Apple(AAPL)$","images":[{"img":"https://community-static.tradeup.com/news/cc47221296177fb1ef93ffc942e187be","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/467325531677376","isVote":1,"tweetType":1,"viewCount":1608,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":464961769689568,"gmtCreate":1754526268701,"gmtModify":1754526272261,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/VOO\">$Vanguard S&amp;P 500 ETF(VOO)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/VOO\">$Vanguard S&amp;P 500 ETF(VOO)$&nbsp;</a>&nbsp;","text":"$Vanguard S&P 500 ETF(VOO)$","images":[{"img":"https://community-static.tradeup.com/news/cc673951c63df4340087feb26dc0c695","width":"972","height":"1631"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/464961769689568","isVote":1,"tweetType":1,"viewCount":1234,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":9056261960,"gmtCreate":1655021829950,"gmtModify":1676535549796,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"htmlText":"Happy 8th Anniversary.I love Tiger as user friendly.Able me to trade in Singapore,Australia,Hongkong,China and US stock market.I am proud owning Tiger stocks too.Prosper together with Tiger.Love the Tiger coin as it becomes my daily routine to read news and accumulate the coins to offset some fees.Good trading platform.Cheers&nbsp;","listText":"Happy 8th Anniversary.I love Tiger as user friendly.Able me to trade in Singapore,Australia,Hongkong,China and US stock market.I am proud owning Tiger stocks too.Prosper together with Tiger.Love the Tiger coin as it becomes my daily routine to read news and accumulate the coins to offset some fees.Good trading platform.Cheers&nbsp;","text":"Happy 8th Anniversary.I love Tiger as user friendly.Able me to trade in Singapore,Australia,Hongkong,China and US stock market.I am proud owning Tiger stocks too.Prosper together with Tiger.Love the Tiger coin as it becomes my daily routine to read news and accumulate the coins to offset some fees.Good trading platform.Cheers","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":23,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9056261960","isVote":1,"tweetType":1,"viewCount":1099,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4112405503246782","authorId":"4112405503246782","name":"pancherry","avatar":"https://community-static.tradeup.com/news/c89c54ad3676d7bcbe6f66034660aa21","crmLevel":12,"crmLevelSwitch":1,"idStr":"4112405503246782","authorIdStr":"4112405503246782"},"content":"all the best","text":"all the best","html":"all the best"},{"author":{"id":"3555293442593045","authorId":"3555293442593045","name":"Samlunch","avatar":"https://static.tigerbbs.com/17478579b111537e74aea4d338e8aef5","crmLevel":12,"crmLevelSwitch":0,"idStr":"3555293442593045","authorIdStr":"3555293442593045"},"content":"Yes! And fractional shares too","text":"Yes! And fractional shares too","html":"Yes! And fractional shares too"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":545976004883376,"gmtCreate":1774306093525,"gmtModify":1774306097077,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/VOO\">$Vanguard S&amp;P 500 ETF(VOO)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/VOO\">$Vanguard S&amp;P 500 ETF(VOO)$&nbsp;</a>&nbsp;","text":"$Vanguard S&P 500 ETF(VOO)$","images":[{"img":"https://community-static.tradeup.com/news/7f778e8a097920fc5447532bba4bfcbc","width":"924","height":"1536"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/545976004883376","isVote":1,"tweetType":1,"viewCount":34,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9096429880,"gmtCreate":1644451574384,"gmtModify":1676533927430,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"htmlText":"Ready to take off","listText":"Ready to take off","text":"Ready to take off","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096429880","repostId":"1154751327","repostType":4,"repost":{"id":"1154751327","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1644419033,"share":"https://ttm.financial/m/news/1154751327?lang=en_US&edition=fundamental","pubTime":"2022-02-09 23:03","market":"us","language":"en","title":"Alibaba Shares Jumped over 3% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1154751327","media":"Tiger Newspress","summary":"Alibaba Shares Jumped over 3% in Morning Trading. Softbank Said Additional Alibaba ADS Not Tied to A","content":"<html><head></head><body><p>Alibaba Shares Jumped over 3% in Morning Trading. Softbank Said Additional Alibaba ADS Not Tied to Any Specific Future Softbank Transaction.<img src=\"https://static.tigerbbs.com/ded43a9d79c85fd086b9d3d2dbcd926d\" tg-width=\"872\" tg-height=\"639\" referrerpolicy=\"no-referrer\"/>Alibaba&#39;s recent registration of additional American Depository Shares is not tied to any specific future transaction by SoftBank Group Corp, a spokesperson for the Japanese conglomerate said on Wednesday.</p><p>&#34;The registration of the ADR conversion facility (F6 filing, which was filed by Alibaba), including its size, is not tied to any specific future transaction by SBG,&#34; SoftBank said in a statement to Reuters.</p><p>E-commerce giant Alibaba last week filed to register an additional one billion American Depository Shares. The move, Citigroup analysts said this week, &#34;might also suggest potential selling intention by SoftBank.&#34;</p><p>&#34;Since Softbank has been a pre-IPO investor, we believe a large proportion of those shares have not been previously registered as ADS,&#34; Citi analysts including Alicia Yap wrote.</p><p>SoftBank&#39;s stake of around 25% in Alibaba is worth around $82 billion and has its origins in a $20 million investment in 2000. Alibaba&#39;s shares have fallen by 60% since highs in October 2020.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alibaba Shares Jumped over 3% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlibaba Shares Jumped over 3% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-09 23:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Alibaba Shares Jumped over 3% in Morning Trading. Softbank Said Additional Alibaba ADS Not Tied to Any Specific Future Softbank Transaction.<img src=\"https://static.tigerbbs.com/ded43a9d79c85fd086b9d3d2dbcd926d\" tg-width=\"872\" tg-height=\"639\" referrerpolicy=\"no-referrer\"/>Alibaba&#39;s recent registration of additional American Depository Shares is not tied to any specific future transaction by SoftBank Group Corp, a spokesperson for the Japanese conglomerate said on Wednesday.</p><p>&#34;The registration of the ADR conversion facility (F6 filing, which was filed by Alibaba), including its size, is not tied to any specific future transaction by SBG,&#34; SoftBank said in a statement to Reuters.</p><p>E-commerce giant Alibaba last week filed to register an additional one billion American Depository Shares. The move, Citigroup analysts said this week, &#34;might also suggest potential selling intention by SoftBank.&#34;</p><p>&#34;Since Softbank has been a pre-IPO investor, we believe a large proportion of those shares have not been previously registered as ADS,&#34; Citi analysts including Alicia Yap wrote.</p><p>SoftBank&#39;s stake of around 25% in Alibaba is worth around $82 billion and has its origins in a $20 million investment in 2000. Alibaba&#39;s shares have fallen by 60% since highs in October 2020.</p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BABA":"阿里巴巴"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154751327","content_text":"Alibaba Shares Jumped over 3% in Morning Trading. Softbank Said Additional Alibaba ADS Not Tied to Any Specific Future Softbank Transaction.Alibaba's recent registration of additional American Depository Shares is not tied to any specific future transaction by SoftBank Group Corp, a spokesperson for the Japanese conglomerate said on Wednesday.\"The registration of the ADR conversion facility (F6 filing, which was filed by Alibaba), including its size, is not tied to any specific future transaction by SBG,\" SoftBank said in a statement to Reuters.E-commerce giant Alibaba last week filed to register an additional one billion American Depository Shares. The move, Citigroup analysts said this week, \"might also suggest potential selling intention by SoftBank.\"\"Since Softbank has been a pre-IPO investor, we believe a large proportion of those shares have not been previously registered as ADS,\" Citi analysts including Alicia Yap wrote.SoftBank's stake of around 25% in Alibaba is worth around $82 billion and has its origins in a $20 million investment in 2000. Alibaba's shares have fallen by 60% since highs in October 2020.","news_type":1,"symbols_score_info":{"BABA":0.9}},"isVote":1,"tweetType":1,"viewCount":616,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":103729700,"gmtCreate":1619825317500,"gmtModify":1704335319673,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"htmlText":"Go for Xpeng&nbsp;","listText":"Go for Xpeng&nbsp;","text":"Go for Xpeng","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":8,"repostSize":0,"link":"https://ttm.financial/post/103729700","repostId":"1137943982","repostType":4,"isVote":1,"tweetType":1,"viewCount":990,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3575326435298567","authorId":"3575326435298567","name":"Angsana","avatar":"https://static.tigerbbs.com/3c8492153d7059ec1aa704a1bd541c14","crmLevel":5,"crmLevelSwitch":0,"idStr":"3575326435298567","authorIdStr":"3575326435298567"},"content":"NIO better lar haha","text":"NIO better lar haha","html":"NIO better lar haha"},{"author":{"id":"3574897713454581","authorId":"3574897713454581","name":"JCai","avatar":"https://static.tigerbbs.com/a4408059854d4abfa5d3e8513d447a16","crmLevel":12,"crmLevelSwitch":0,"idStr":"3574897713454581","authorIdStr":"3574897713454581"},"content":"respond pls thanks!","text":"respond pls thanks!","html":"respond pls thanks!"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":881448263,"gmtCreate":1631396669052,"gmtModify":1676530539266,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"htmlText":"Yes,definitely is a good investment in these companies&nbsp;","listText":"Yes,definitely is a good investment in these companies&nbsp;","text":"Yes,definitely is a good investment in these companies","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/881448263","repostId":"2166375184","repostType":4,"isVote":1,"tweetType":1,"viewCount":759,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":812080029,"gmtCreate":1630541332261,"gmtModify":1676530333073,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"htmlText":"Good sign&nbsp;","listText":"Good sign&nbsp;","text":"Good sign","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/812080029","repostId":"2164481914","repostType":4,"isVote":1,"tweetType":1,"viewCount":609,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896047938,"gmtCreate":1628548683024,"gmtModify":1703507779074,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"htmlText":"Unbelievable&nbsp;","listText":"Unbelievable&nbsp;","text":"Unbelievable","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":7,"repostSize":0,"link":"https://ttm.financial/post/896047938","repostId":"1178202513","repostType":4,"isVote":1,"tweetType":1,"viewCount":717,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":103905446,"gmtCreate":1619741594485,"gmtModify":1704271605263,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"htmlText":"Only can stare at the share price","listText":"Only can stare at the share price","text":"Only can stare at the share price","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":9,"repostSize":0,"link":"https://ttm.financial/post/103905446","repostId":"1188611661","repostType":4,"repost":{"id":"1188611661","kind":"news","pubTimestamp":1619734487,"share":"https://ttm.financial/m/news/1188611661?lang=en_US&edition=fundamental","pubTime":"2021-04-30 06:14","market":"us","language":"en","title":"Amazon sales surge 44% as it smashes earnings expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=1188611661","media":"CNBC","summary":"Amazon released first-quarter results on Thursday that trounced analysts’ expectations.\nThe company ","content":"<ul>\n <li>Amazon released first-quarter results on Thursday that trounced analysts’ expectations.</li>\n <li>The company confirmed that this year’s Prime Day will take place in June, which will likely help year over year comparisons for revenue in the second quarter.</li>\n</ul>\n<p>Amazonshares climbed more than 3.5% in extended trading Thursday after the company&nbsp;released&nbsp;its first-quarter earnings, beating Wall Street’s expectations for earnings and revenue.</p>\n<p><img src=\"https://static.tigerbbs.com/798d7f0536203d2ae33b543f4dabf204\" tg-width=\"1281\" tg-height=\"591\"></p>\n<p>Here’s how the e-commerce giant fared, relative to analyst estimates compiled by Refinitiv:</p>\n<ul>\n <li><b>Earnings:</b>$15.79 per share vs. $9.54 per share expected</li>\n <li><b>Revenue:</b>$108.52 billion vs. $104.47 billion expected</li>\n</ul>\n<p>Few companies have benefited from the pandemic-fueled surge of online shoppingas much as Amazon. Its first-quarter results showed the company’s business continues to be buoyed by the pandemic, with sales soaring 44% year-over-year to $108.5 billion.</p>\n<p>Amazon’s guidance for the second quarter implies that it expects the momentum to continue, which should help allay investor fears that business could slow in a post-pandemic environment. The company expects to post revenue between $110 billion and $116 billion, surpassing Wall Street’s projection $108.6 billion.</p>\n<p>Crucially, Amazon confirmed in its guidance that this year’s Prime Day will take place in June, which will likely help year-over-year comparisons for revenue in the second quarter. Typically, Amazon’s annual, two-day discount bonanza takes place in July, but the company postponed the event to October last year amid pandemic-related uncertainty.</p>\n<p>When asked about the Prime Day timing, CFO Brian Olsavsky said on a call with investors: “In many areas, July is vacation month, so it might be better for customers, sellers and vendors to experiment with a different time period. We believe that it might be better timing later in [the second quarter], so that’s what we’re testing this year.”</p>\n<p>Outside of its core retail segment, Amazon’s cloud-computing and advertising businesses continue to boom. Amazon Web Servicessawnet sales of $13.5 billion during the quarter, up 32% year over year. Amazon doesn’t disclose advertising sales, but it’s included in the company’s “Other” category, which saw its revenues grow 77% year over year to $6.9 billion.</p>\n<p>Amazon CEO Jeff Bezos also gave a rare glimpse into how the company’s streaming business has fared during the pandemic, as stuck-at-home consumers relied on online entertainment to keep busy. “As Prime Video turns 10, over 175 million Prime members have streamed shows and movies in the past year, and streaming hours are up more than 70% year over year,” he said.</p>\n<p>Amazon’s streaming service, Prime Video, is a key offering of the company’s Prime subscription service, which costs $119 a year and includes a range of other benefits like free, two-day shipping. Bezos disclosed earlier this month that the company now has 200 million Prime subscribers, 50 million more than it had at the start of 2020.</p>\n<p>Physical stores revenue, which includes Whole Foods Market and other brick-and-mortar offerings like Amazon Books, continued to fall. Sales slumped 16% to $3.9 billion. The category excludes online delivery, Olsavsky said.</p>\n<p>During the quarter, Amazon’s sales grew faster internationally than they did in North America. International revenue surged 60% year over year, more than any other segment, while North America revenue climbed 40%.</p>\n<p>As expected, Amazon will incur fewer costs this year related to coronavirus safety measures. Operating income is forecast to be between $4.5 billion and $8 billion in the second quarter, assuming $1.5 billion of costs related to Covid-19. That’s in line with what Amazon executives predicted last quarter.</p>\n<p>AmazonsaidWednesday it would spend more than $1 billion on raising wages for over half a million of its U.S. operations workers. On a call with reporters, Olsavsky said it decided to move up the pay increase from the fall to this spring as volumes remain just as strong as they were at the beginning of the pandemic.</p>\n<p>Olsavsky declined to comment on Amazon’s CEO transition plans, which will come into play once Bezossteps down in the third quarter. Bezos will turn the helm over to AWS CEO Andy Jassy and assume the role of executive chairman of Amazon’s board.</p>","source":"lsy1609915699154","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon sales surge 44% as it smashes earnings expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon sales surge 44% as it smashes earnings expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-30 06:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/29/amazon-amzn-earnings-q1-2021.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amazon released first-quarter results on Thursday that trounced analysts’ expectations.\nThe company confirmed that this year’s Prime Day will take place in June, which will likely help year over year ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/29/amazon-amzn-earnings-q1-2021.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"source_url":"https://www.cnbc.com/2021/04/29/amazon-amzn-earnings-q1-2021.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188611661","content_text":"Amazon released first-quarter results on Thursday that trounced analysts’ expectations.\nThe company confirmed that this year’s Prime Day will take place in June, which will likely help year over year comparisons for revenue in the second quarter.\n\nAmazonshares climbed more than 3.5% in extended trading Thursday after the company released its first-quarter earnings, beating Wall Street’s expectations for earnings and revenue.\n\nHere’s how the e-commerce giant fared, relative to analyst estimates compiled by Refinitiv:\n\nEarnings:$15.79 per share vs. $9.54 per share expected\nRevenue:$108.52 billion vs. $104.47 billion expected\n\nFew companies have benefited from the pandemic-fueled surge of online shoppingas much as Amazon. Its first-quarter results showed the company’s business continues to be buoyed by the pandemic, with sales soaring 44% year-over-year to $108.5 billion.\nAmazon’s guidance for the second quarter implies that it expects the momentum to continue, which should help allay investor fears that business could slow in a post-pandemic environment. The company expects to post revenue between $110 billion and $116 billion, surpassing Wall Street’s projection $108.6 billion.\nCrucially, Amazon confirmed in its guidance that this year’s Prime Day will take place in June, which will likely help year-over-year comparisons for revenue in the second quarter. Typically, Amazon’s annual, two-day discount bonanza takes place in July, but the company postponed the event to October last year amid pandemic-related uncertainty.\nWhen asked about the Prime Day timing, CFO Brian Olsavsky said on a call with investors: “In many areas, July is vacation month, so it might be better for customers, sellers and vendors to experiment with a different time period. We believe that it might be better timing later in [the second quarter], so that’s what we’re testing this year.”\nOutside of its core retail segment, Amazon’s cloud-computing and advertising businesses continue to boom. Amazon Web Servicessawnet sales of $13.5 billion during the quarter, up 32% year over year. Amazon doesn’t disclose advertising sales, but it’s included in the company’s “Other” category, which saw its revenues grow 77% year over year to $6.9 billion.\nAmazon CEO Jeff Bezos also gave a rare glimpse into how the company’s streaming business has fared during the pandemic, as stuck-at-home consumers relied on online entertainment to keep busy. “As Prime Video turns 10, over 175 million Prime members have streamed shows and movies in the past year, and streaming hours are up more than 70% year over year,” he said.\nAmazon’s streaming service, Prime Video, is a key offering of the company’s Prime subscription service, which costs $119 a year and includes a range of other benefits like free, two-day shipping. Bezos disclosed earlier this month that the company now has 200 million Prime subscribers, 50 million more than it had at the start of 2020.\nPhysical stores revenue, which includes Whole Foods Market and other brick-and-mortar offerings like Amazon Books, continued to fall. Sales slumped 16% to $3.9 billion. The category excludes online delivery, Olsavsky said.\nDuring the quarter, Amazon’s sales grew faster internationally than they did in North America. International revenue surged 60% year over year, more than any other segment, while North America revenue climbed 40%.\nAs expected, Amazon will incur fewer costs this year related to coronavirus safety measures. Operating income is forecast to be between $4.5 billion and $8 billion in the second quarter, assuming $1.5 billion of costs related to Covid-19. That’s in line with what Amazon executives predicted last quarter.\nAmazonsaidWednesday it would spend more than $1 billion on raising wages for over half a million of its U.S. operations workers. On a call with reporters, Olsavsky said it decided to move up the pay increase from the fall to this spring as volumes remain just as strong as they were at the beginning of the pandemic.\nOlsavsky declined to comment on Amazon’s CEO transition plans, which will come into play once Bezossteps down in the third quarter. Bezos will turn the helm over to AWS CEO Andy Jassy and assume the role of executive chairman of Amazon’s board.","news_type":1,"symbols_score_info":{"AMZN":0.9}},"isVote":1,"tweetType":1,"viewCount":733,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3578111487107537","authorId":"3578111487107537","name":"Chimpsey","avatar":"https://static.tigerbbs.com/ab58cb989ba2205bb2646f1c4d97c579","crmLevel":12,"crmLevelSwitch":0,"idStr":"3578111487107537","authorIdStr":"3578111487107537"},"content":"Already so high","text":"Already so high","html":"Already so high"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860612239,"gmtCreate":1632175341921,"gmtModify":1676530715590,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"htmlText":"Getting ready and trade safely&nbsp;","listText":"Getting ready and trade safely&nbsp;","text":"Getting ready and trade safely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":14,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/860612239","repostId":"1124728794","repostType":4,"repost":{"id":"1124728794","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632154404,"share":"https://ttm.financial/m/news/1124728794?lang=en_US&edition=fundamental","pubTime":"2021-09-21 00:13","market":"us","language":"en","title":"Market sell-off worsens with Dow dropping 650 points, S&P 500 losing 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124728794","media":"Tiger Newspress","summary":"(Sept 21)&nbsp;Market sell-off worsens with Dow dropping 650 points, S&P 500 losing 2%.","content":"<p>(Sept 21)&nbsp;Market sell-off worsens with Dow dropping 650 points, S&amp;P 500 losing 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/b1aff42b5f28f13e23dc15c6bee909d3\" tg-width=\"350\" tg-height=\"130\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market sell-off worsens with Dow dropping 650 points, S&P 500 losing 2%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket sell-off worsens with Dow dropping 650 points, S&P 500 losing 2%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-21 00:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Sept 21)&nbsp;Market sell-off worsens with Dow dropping 650 points, S&amp;P 500 losing 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/b1aff42b5f28f13e23dc15c6bee909d3\" tg-width=\"350\" tg-height=\"130\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124728794","content_text":"(Sept 21) Market sell-off worsens with Dow dropping 650 points, S&P 500 losing 2%.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":961,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":836268788,"gmtCreate":1629501599244,"gmtModify":1676530058088,"author":{"id":"3559787818034959","authorId":"3559787818034959","name":"Ericlam","avatar":"https://static.tigerbbs.com/f2154f4bb8afd22f8e6fde60b57acb69","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559787818034959","authorIdStr":"3559787818034959"},"themes":[],"htmlText":"Stay invested&nbsp;","listText":"Stay invested&nbsp;","text":"Stay invested","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/836268788","repostId":"2161743232","repostType":4,"repost":{"id":"2161743232","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1629489634,"share":"https://ttm.financial/m/news/2161743232?lang=en_US&edition=fundamental","pubTime":"2021-08-21 04:00","market":"us","language":"en","title":"Wall Street rallies as Fed jitters ease, but posts weekly loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2161743232","media":"Reuters","summary":"NEW YORK, Aug 20 (Reuters) - Wall Street rallied to close sharply higher at the close of a tumultuou","content":"<p>NEW YORK, Aug 20 (Reuters) - Wall Street rallied to close sharply higher at the close of a tumultuous week on waning concerns over whether the U.S. Federal Reserve could begin tightening its dovish monetary policy sooner than expected.</p>\n<p>While all three major U.S. indexes ended solidly green, all posted weekly losses after a steep mid-week sell-off pulled the S&amp;P 500 and the Dow away from a string of record closing highs.</p>\n<p>\"Towards the beginning of the week you saw traders balancing their books ahead of the Fed statement,\" said Matthew Keator, managing partner in the Keator Group, a wealth management firm in Lenox, Massachusetts. \"And once the statement came out, you saw a bit of 'sell the rumor buy the news.'\"</p>\n<p>Market-leading tech and tech-adjacent megacaps, which weathered the pandemic recession better than most, once again provided the biggest boost.</p>\n<p>Growth stocks were also given a boost by U.S. Treasury yields, which ended the week lower due to concerns the health crisis could be a longer than expected hindrance to economic revival.</p>\n<p>Announcements from a host of Asian nations that they are implementing drastic measures to curb the resurgence of COVID-19 due to the rise of the disease's highly contagious Delta variant, put a damper on stocks associated with economic re-engagement.</p>\n<p>Mixed economic data from the U.S. and China suggested the ongoing recovery from the most abrupt recession on record has passed its peak and lost some momentum.</p>\n<p>Market participants now look to next week's Jackson Hole Symposium, a gathering of major central bank leaders, for clues from Fed Chair Jerome Powell regarding the expected pace of recovery and the timeline for policy tightening.</p>\n<p>\"We’ve seen times in history where the Jackson Hole Symposium has drawn a lot of eyeballs but this year more so,\" Keator added. \"The Fed might use this opportunity to communicate what their plan is going forward.\"</p>\n<p>Unofficially, the Dow Jones Industrial Average rose 222.15 points, or 0.64%, to 35,116.27, the S&amp;P 500 gained 35.79 points, or 0.81%, to 4,441.59 and the Nasdaq Composite&nbsp;added 169.95 points, or 1.17%, to 14,711.73.</p>\n<p>All 11 major sectors of the S&amp;P 500 ended the session higher.</p>\n<p>Second-quarter reporting season has essentially run its course, with 476 of the companies in the S&amp;P 500 having posted results. Of those, 87.4% have beaten consensus, according to Refinitiv data.</p>\n<p>Farm and construction equipment manufacturer Deere &amp; Co&nbsp;beat quarterly profit expectations and raised its full year guidance due to robust demand . Still, its shares lost ground.</p>\n<p>Bristol-Myers Squibb advanced after the U.S. Food and Drug Administration approved the drugmaker's cancer drug Opdivo.</p>\n<p>U.S.-listed shares of China-based tech-related companies oscillated as market participants digested recent sell-offs resulting from Beijing's ongoing regulatory crackdown, which has wiped half a trillion dollars from Chinese markets this week.</p>\n<p>(Reporting by Stephen Culp; Additional reporting by Devik Jain and Medha Singh in Bengaluru; Editing by Aurora Ellis)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street rallies as Fed jitters ease, but posts weekly loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street rallies as Fed jitters ease, but posts weekly loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-21 04:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, Aug 20 (Reuters) - Wall Street rallied to close sharply higher at the close of a tumultuous week on waning concerns over whether the U.S. Federal Reserve could begin tightening its dovish monetary policy sooner than expected.</p>\n<p>While all three major U.S. indexes ended solidly green, all posted weekly losses after a steep mid-week sell-off pulled the S&amp;P 500 and the Dow away from a string of record closing highs.</p>\n<p>\"Towards the beginning of the week you saw traders balancing their books ahead of the Fed statement,\" said Matthew Keator, managing partner in the Keator Group, a wealth management firm in Lenox, Massachusetts. \"And once the statement came out, you saw a bit of 'sell the rumor buy the news.'\"</p>\n<p>Market-leading tech and tech-adjacent megacaps, which weathered the pandemic recession better than most, once again provided the biggest boost.</p>\n<p>Growth stocks were also given a boost by U.S. Treasury yields, which ended the week lower due to concerns the health crisis could be a longer than expected hindrance to economic revival.</p>\n<p>Announcements from a host of Asian nations that they are implementing drastic measures to curb the resurgence of COVID-19 due to the rise of the disease's highly contagious Delta variant, put a damper on stocks associated with economic re-engagement.</p>\n<p>Mixed economic data from the U.S. and China suggested the ongoing recovery from the most abrupt recession on record has passed its peak and lost some momentum.</p>\n<p>Market participants now look to next week's Jackson Hole Symposium, a gathering of major central bank leaders, for clues from Fed Chair Jerome Powell regarding the expected pace of recovery and the timeline for policy tightening.</p>\n<p>\"We’ve seen times in history where the Jackson Hole Symposium has drawn a lot of eyeballs but this year more so,\" Keator added. \"The Fed might use this opportunity to communicate what their plan is going forward.\"</p>\n<p>Unofficially, the Dow Jones Industrial Average rose 222.15 points, or 0.64%, to 35,116.27, the S&amp;P 500 gained 35.79 points, or 0.81%, to 4,441.59 and the Nasdaq Composite&nbsp;added 169.95 points, or 1.17%, to 14,711.73.</p>\n<p>All 11 major sectors of the S&amp;P 500 ended the session higher.</p>\n<p>Second-quarter reporting season has essentially run its course, with 476 of the companies in the S&amp;P 500 having posted results. Of those, 87.4% have beaten consensus, according to Refinitiv data.</p>\n<p>Farm and construction equipment manufacturer Deere &amp; Co&nbsp;beat quarterly profit expectations and raised its full year guidance due to robust demand . Still, its shares lost ground.</p>\n<p>Bristol-Myers Squibb advanced after the U.S. Food and Drug Administration approved the drugmaker's cancer drug Opdivo.</p>\n<p>U.S.-listed shares of China-based tech-related companies oscillated as market participants digested recent sell-offs resulting from Beijing's ongoing regulatory crackdown, which has wiped half a trillion dollars from Chinese markets this week.</p>\n<p>(Reporting by Stephen Culp; Additional reporting by Devik Jain and Medha Singh in Bengaluru; Editing by Aurora Ellis)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF博时","DOG":"道指ETF-ProShares做空","SH":"做空标普500-Proshares","PSQ":"做空纳斯达克100指数ETF-ProShares","IVV":"标普500ETF-iShares","SDOW":"三倍做空道指30ETF-ProShares","DXD":"两倍做空道琼30指数ETF-ProShares","DDM":"2倍做多道指ETF-ProShares","QQQ":"纳指100ETF","SDS":"两倍做空标普500 ETF-ProShares",".SPX":"S&P 500 Index","SQQQ":"纳指三倍做空ETF","UDOW":"三倍做多道指30ETF-ProShares","OEF":"标普100指数ETF-iShares",".DJI":"道琼斯","QLD":"2倍做多纳斯达克100指数ETF-ProShares","SPXU":"三倍做空标普500ETF-ProShares","OEX":"标普100","UPRO":"三倍做多标普500ETF-ProShares","SSO":"2倍做多标普500ETF-ProShares","DJX":"1/100道琼斯","TQQQ":"纳指三倍做多ETF","QID":"两倍做空纳斯达克指数ETF-ProShares",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161743232","content_text":"NEW YORK, Aug 20 (Reuters) - Wall Street rallied to close sharply higher at the close of a tumultuous week on waning concerns over whether the U.S. Federal Reserve could begin tightening its dovish monetary policy sooner than expected.\nWhile all three major U.S. indexes ended solidly green, all posted weekly losses after a steep mid-week sell-off pulled the S&P 500 and the Dow away from a string of record closing highs.\n\"Towards the beginning of the week you saw traders balancing their books ahead of the Fed statement,\" said Matthew Keator, managing partner in the Keator Group, a wealth management firm in Lenox, Massachusetts. \"And once the statement came out, you saw a bit of 'sell the rumor buy the news.'\"\nMarket-leading tech and tech-adjacent megacaps, which weathered the pandemic recession better than most, once again provided the biggest boost.\nGrowth stocks were also given a boost by U.S. Treasury yields, which ended the week lower due to concerns the health crisis could be a longer than expected hindrance to economic revival.\nAnnouncements from a host of Asian nations that they are implementing drastic measures to curb the resurgence of COVID-19 due to the rise of the disease's highly contagious Delta variant, put a damper on stocks associated with economic re-engagement.\nMixed economic data from the U.S. and China suggested the ongoing recovery from the most abrupt recession on record has passed its peak and lost some momentum.\nMarket participants now look to next week's Jackson Hole Symposium, a gathering of major central bank leaders, for clues from Fed Chair Jerome Powell regarding the expected pace of recovery and the timeline for policy tightening.\n\"We’ve seen times in history where the Jackson Hole Symposium has drawn a lot of eyeballs but this year more so,\" Keator added. \"The Fed might use this opportunity to communicate what their plan is going forward.\"\nUnofficially, the Dow Jones Industrial Average rose 222.15 points, or 0.64%, to 35,116.27, the S&P 500 gained 35.79 points, or 0.81%, to 4,441.59 and the Nasdaq Composite added 169.95 points, or 1.17%, to 14,711.73.\nAll 11 major sectors of the S&P 500 ended the session higher.\nSecond-quarter reporting season has essentially run its course, with 476 of the companies in the S&P 500 having posted results. Of those, 87.4% have beaten consensus, according to Refinitiv data.\nFarm and construction equipment manufacturer Deere & Co beat quarterly profit expectations and raised its full year guidance due to robust demand . Still, its shares lost ground.\nBristol-Myers Squibb advanced after the U.S. Food and Drug Administration approved the drugmaker's cancer drug Opdivo.\nU.S.-listed shares of China-based tech-related companies oscillated as market participants digested recent sell-offs resulting from Beijing's ongoing regulatory crackdown, which has wiped half a trillion dollars from Chinese markets this week.\n(Reporting by Stephen Culp; Additional reporting by Devik Jain and Medha Singh in Bengaluru; Editing by Aurora Ellis)","news_type":1,"symbols_score_info":{"161125":0.9,"513500":0.9,"DOG":0.9,"ESmain":0.9,"NQmain":0.9,".DJI":0.9,"DXD":0.9,"PSQ":0.9,"SH":0.9,".SPX":0.9,"DDM":0.9,".IXIC":0.9,"QLD":0.9,"OEX":0.9,"UDOW":0.9,"QID":0.9,"SQQQ":0.9,"SDS":0.9,"SPXU":0.9,"DJX":0.9,"SDOW":0.9,"UPRO":0.9,"OEF":0.9,"SSO":0.9,"MNQmain":0.9,"IVV":0.9,"QQQ":0.9,"TQQQ":0.9}},"isVote":1,"tweetType":1,"viewCount":665,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3553658931361428","authorId":"3553658931361428","name":"yaozong7","avatar":"https://community-static.tradeup.com/news/0db82c58fe151c6056334e54bf8ceeee","crmLevel":4,"crmLevelSwitch":0,"idStr":"3553658931361428","authorIdStr":"3553658931361428"},"content":"Always! But in ETFs.","text":"Always! But in ETFs.","html":"Always! But in ETFs."}],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}